Investor Resources
Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019
Presentations:
Title: Final Results from the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in
Session: P18. Neuroendocrinology and Pituitary.
Poster: SAT-429.
Date and Time:
Location: ENDOExpo.
This poster will also be given as a Guided Poster presentation.
Session: Guided Posters: Neuroendocrinology and Pituitary
Poster: GP22.
Date and Time:
Location: ENDOExpo, Booth 2745
Title: Nonpeptide Orally-Bioavailable ACTH Antagonists: Suppression of ACTH-Induced Corticosterone Secretion and Adrenal Hypertrophy in Rats
Session: P15. Adrenal Basic and Translational Pathways.
Poster: SAT-364.
Date and Time:
Location: ENDOExpo.
This poster will also be given as a Guided Poster presentation.
Session: Guided Posters: Adrenal (excluding mineralocorticoids)
Poster: GP21.
Date and Time:
Location: ENDOExpo, Booth 2545
Title: Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists Suppress Glucose- and Sulfonylurea-Induced Insulin Secretion in Rats
Session: P07. Novel Aspects of Diabetes and Metabolic Disease Across Tissues and Developmental Stages
Poster: SAT-169.
Date and Time:
Location: ENDOExpo.
Title: Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists Suppress Induced Insulin Secretion in Pancreatic Islets from both Rats and Healthy Human Donors
Session: P10. General Pediatric Endocrinology, Autoimmune Polyglandular Syndrome, Obesity, and Metabolic Syndrome
Poster: SAT-260.
Date and Time:
Location: ENDOExpo.
After the presentations at ENDO2019, the posters will be available on the Crinetics company website at: https://www.crinetics.com/our-approach/
About
Contacts:
Chief Financial Officer
IR@crinetics.com
(858) 450-6464
Westwicke Partners
robert.uhl@westwicke.com
(858) 356-5932
Source: Crinetics Pharmaceuticals, Inc.